The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|9|6|482-503

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.9, Iss.6, 2009-04, pp. : 482-503

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite

Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash   Henderson David C  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite

Orlistat: its current status as an anti-obesity drug

By Ballinger A.   Peikin S.R.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 109-117

Elsevier

Access to resources Recommend Favorite

NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 17, 2007-01 ,pp. : 1721-1733

Bentham Science Publishers

Access to resources Recommend Favorite

Serotonergic Anti-Obesity Agents: Past Experience and Future Prospects

By Halford Jason C.G.  

Drugs, Vol. 71, Iss. 17, 2011-12 ,pp. : 2247-2255

Adis International

Access to resources Recommend Favorite